Institution
University of Kansas
Education•Lawrence, Kansas, United States•
About: University of Kansas is a education organization based out in Lawrence, Kansas, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 38183 authors who have published 81381 publications receiving 2986312 citations. The organization is also known as: KU & Univ of Kansas.
Topics: Population, Poison control, Large Hadron Collider, Health care, Cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: The taxonomy and models for categorical item response data may usefully be organized as members of only three distinct classes, within which the models are distinguished only by assumptions and constraints on their parameters.
Abstract: A number of models for categorical item response data have been proposed in recent years. The models appear to be quite different. However, they may usefully be organized as members of only three distinct classes, within which the models are distinguished only by assumptions and constraints on their parameters. “Difference models” are appropriate for ordered responses, “divide-by-total” models may be used for either ordered or nominal responses, and “left-side added” models are used for multiple-choice responses with guessing. The details of the taxonomy and the models are described in this paper.
381 citations
Yeshiva University1, University of Kansas2, United States Department of Veterans Affairs3, Icahn School of Medicine at Mount Sinai4, University of Florida5, Institute of Medical Science6, Medical University of South Carolina7, University of Michigan8, University of Southern California9, University of Pittsburgh10, University of Chicago11, Saint Louis University12, Indiana University – Purdue University Indianapolis13
TL;DR: This review summarizes recent advances in understanding the roles that autophagy plays in normal hepatic physiology and pathophysiology with the intent of furthering the development of autophileagy-based therapies for human liver diseases.
Abstract: Autophagy has emerged as a critical lysosomal pathway that maintains cell function and survival through the degradation of cellular components such as organelles and proteins. Investigations specifically employing the liver or hepatocytes as experimental models have contributed significantly to our current knowledge of autophagic regulation and function. The diverse cellular functions of autophagy, along with unique features of the liver and its principal cell type the hepatocyte, suggest that the liver is highly dependent on autophagy for both normal function and to prevent the development of disease states. However, instances have also been identified in which autophagy promotes pathological changes such as the development of hepatic fibrosis. Considerable evidence has accumulated that alterations in autophagy are an underlying mechanism of a number of common hepatic diseases including toxin-, drug- and ischemia/reperfusion-induced liver injury, fatty liver, viral hepatitis and hepatocellular carcinoma. This review summarizes recent advances in understanding the roles that autophagy plays in normal hepatic physiology and pathophysiology with the intent of furthering the development of autophagy-based therapies for human liver diseases.
381 citations
Cleveland Clinic1, Fred Hutchinson Cancer Research Center2, Peter MacCallum Cancer Centre3, University of Sydney4, Mater Health Services5, Fox Chase Cancer Center6, Harvard University7, University of Southern California8, University of Washington9, University of Kansas10, National Institutes of Health11, University of California, Irvine12, University of Texas MD Anderson Cancer Center13, Loyola University Chicago14
TL;DR: Although missing data weaken interpretation of the findings, administration of goserelin with chemotherapy appeared to protect against ovarian failure, reducing the risk of early menopause and improving prospects for fertility.
Abstract: BackgroundOvarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes. MethodsWe randomly assigned 257 premenopausal women with operable hormone-receptor–negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group). The primary study end point was the rate of ovarian failure at 2 years, with ovarian failure defined as the absence of menses in the preceding 6 months and levels of follicle-stimulating hormone (FSH) in the postmenopausal range. Rates were compared with the use of conditional logistic regression. Secondary end points included pregnancy outcomes and disease-free and overall survival. ResultsAt baseline, 218 patients were eligible and could be evaluated. Among 135 with complete primary end-point data, the ovarian failure rate wa...
381 citations
Icahn School of Medicine at Mount Sinai1, National Institutes of Health2, Bronson Methodist Hospital3, Rush University Medical Center4, University of Kansas5, University of Maryland, Baltimore6, Geisinger Health System7, Kaiser Permanente8, Baylor College of Medicine9, Augsburg College10, Stanford University11, University of Alberta12
TL;DR: The 2008 AAN guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia, headache, and adult spasticity are updated and onaBoNT-A is established as ineffective and should not be offered for episodic migraine and is probably ineffective for chronic tension-type headaches.
Abstract: Objective: To update the 2008 American Academy of Neurology (AAN) guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia (CD), headache, and adult spasticity. Methods: We searched the literature for relevant articles and classified them using 2004 AAN criteria. Results and recommendations: Blepharospasm: OnabotulinumtoxinA (onaBoNT-A) and incobotulinumtoxinA (incoBoNT-A) are probably effective and should be considered (Level B). AbobotulinumtoxinA (aboBoNT-A) is possibly effective and may be considered (Level C). CD: AboBoNT-A and rimabotulinumtoxinB (rimaBoNT-B) are established as effective and should be offered (Level A), and onaBoNT-A and incoBoNT-A are probably effective and should be considered (Level B). Adult spasticity: AboBoNT-A, incoBoNT-A, and onaBoNT-A are established as effective and should be offered (Level A), and rimaBoNT-B is probably effective and should be considered (Level B), for upper limb spasticity. AboBoNT-A and onaBoNT-A are established as effective and should be offered (Level A) for lower-limb spasticity. Headache: OnaBoNT-A is established as effective and should be offered to increase headache-free days (Level A) and is probably effective and should be considered to improve health-related quality of life (Level B) in chronic migraine. OnaBoNT-A is established as ineffective and should not be offered for episodic migraine (Level A) and is probably ineffective for chronic tension-type headaches (Level B).
380 citations
Hong Kong Polytechnic University1, Odense University Hospital2, Albert Einstein College of Medicine3, University of Texas MD Anderson Cancer Center4, University of Kansas5, University of Toronto6, Indiana University – Purdue University Indianapolis7, Martin Luther University of Halle-Wittenberg8, University of South Australia9, University of Rochester Medical Center10, Princess Margaret Cancer Centre11, Boston Children's Hospital12
TL;DR: The present research presents a novel and scalable approach that combines traditional and regenerative approaches to oncology that has real-time, real-world implications for individual patient care and quality of life.
379 citations
Authors
Showing all 38401 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Gordon H. Guyatt | 231 | 1620 | 228631 |
| Krzysztof Matyjaszewski | 169 | 1431 | 128585 |
| Wei Li | 158 | 1855 | 124748 |
| David Tilman | 158 | 340 | 149473 |
| Tomas Hökfelt | 158 | 1033 | 95979 |
| Pete Smith | 156 | 2464 | 138819 |
| Daniel J. Rader | 155 | 1026 | 107408 |
| Melody A. Swartz | 148 | 1304 | 103753 |
| Kevin Murphy | 146 | 728 | 120475 |
| Carlo Rovelli | 146 | 1502 | 103550 |
| Stephen Sanders | 145 | 1385 | 105943 |
| Marco Zanetti | 145 | 1439 | 104610 |
| Andrei Gritsan | 143 | 1531 | 135398 |
| Gunther Roland | 141 | 1471 | 100681 |
| Joseph T. Hupp | 141 | 731 | 82647 |